seekingalpha.com
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Profound Medical Corp.PROFNASDAQ
Loading
Latest News
Loading news...
zacks.com
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
zacks.com
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
globenewswire.com
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care
globenewswire.com
Profound Medical Corp. Announces Closing of Private Placement
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).
globenewswire.com
Profound Medical Corp. Announces Upsize of Private Placement
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.
globenewswire.com
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders
globenewswire.com
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.
zacks.com
Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet
The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
globenewswire.com
Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation
– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target –
globenewswire.com
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption
zacks.com
Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?
Profound Medical (PROF) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PROF's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
zacks.com
Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
globenewswire.com
Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy
seekingalpha.com
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Profound Medical Corp. ( PRN:CA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Rashed Dewan Mathieu Burtnyk - President Thomas Tamberrino - Chief Commercial Officer Arun Menawat - Chairman of the Board & CEO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Freeman - Raymond James Ltd., Research Division Presentation Operator Good day, and thank you for standing by.
zacks.com
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.38 per share a year ago.
globenewswire.com
Profound Medical Reports Strong Third Quarter 2025 Financial Results
TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).